# Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)

> **NCT07134101** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 138 (estimated)

## Conditions studied

- Colorectal Cancer (Diagnosis)

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Bevacizumab
- **RADIATION:** Short-Course Radioterapy
- **DRUG:** Chemotherapy (CAPOX or capecitabine)

## Key facts

- **NCT ID:** NCT07134101
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134101, "Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07134101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*